REPLIGEN CORP

RGEN · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $6.6B · 2,000 employees
286
SEC Filings
$123.95
Close 2026-05-29
2,000
Employees

Business Summary

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems for biological drug manufacturing. Products span four franchises: Filtration (XCell ATF, KrosFlo TFF, hollow fiber filters), Chromatography (OPUS columns, BioSMB systems), Process Analytics (FlowVPX, SciLog), and Proteins (Protein A ligands). Customers include global biopharmaceutical companies, contract development and manufacturing organizations, and life science integrators producing mAbs, RNA therapeutics, vaccines, and cell and gene therapies.

Latest Stock Quote

RGEN 2026-05-29 $123.95 O:$122.82 H:$125.595 L:$121.81 Vol:0.9M VWAP:$124.1011
origin leaf: 1a8296ce6f8ba906eb1676b273ac161dfcd74b0e98ad478449b8569f79775ce1

Next Earnings

Q2 FY2026 — expected 2026-09-18

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310001193125-26-076528EDGAR62K words
2025-03-142024-12-310000950170-25-038999EDGAR
2024-02-222023-12-310000950170-24-018809EDGAR
2023-02-222022-12-310000950170-23-003793EDGAR
2022-02-172021-12-310000950170-22-001430EDGAR
2021-02-242020-12-310001193125-21-054675EDGAR
2020-02-262019-12-310001193125-20-050136EDGAR
2019-03-012018-12-310001193125-19-060645EDGAR
2018-02-222017-12-310001193125-18-054262EDGAR
2017-02-232016-12-310001193125-17-054220EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-042025-09-300001193125-25-264666EDGAR26K words
2025-08-072025-06-300000950170-25-105166EDGAR
2025-04-292025-03-310000950170-25-060156EDGAR
2024-11-182024-09-300000950170-24-127846EDGAR
2024-07-302024-06-300000950170-24-087981EDGAR
2024-05-012024-03-310000950170-24-051310EDGAR
2023-10-312023-09-300000950170-23-056871EDGAR
2023-08-022023-06-300000950170-23-037204EDGAR
2023-05-022023-03-310000950170-23-016729EDGAR
2022-11-012022-09-300000950170-22-020864EDGAR
2022-08-022022-06-300000950170-22-013883EDGAR
2022-04-272022-03-310000950170-22-006373EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-240001193125-26-065246EDGAR9K words
2026-01-060001193125-26-003467EDGAR
2025-10-280001193125-25-252385EDGAR
2025-09-020001193125-25-193481EDGAR
2025-07-290000950170-25-099389EDGAR
2025-05-150000950170-25-072664EDGAR
2025-04-290000950170-25-059569EDGAR
2025-02-200000950170-25-023742EDGAR
2024-11-120001193125-24-255167EDGAR
2024-09-180001193125-24-221406EDGAR

286 total filings indexed. 254 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Tags

biopharmaceutical-manufacturing contract-development-and-manufacturing-organizations-(cdmos) monoclonal-antibodies-and-mab-derivatives cell-and-gene-therapy-manufacturing rna-based-therapeutics-and-vaccines recombinant-proteins cgmp-(current-good-manufacturing-practice) single-use/single-campaign-bioprocessing closed-system-technologies

Company Identity

CIK0000730272
TickerRGEN
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE
HeadquartersWaltham, Massachusetts
Websitehttps://www.repligen.com
Listed1986-04-29

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 96029da1688aede85a1852b82e684a840f4d491d817e517f135932e6e4629451
parent: 5a6c3757c008ada14282880cbd09935ae2eb87c005bacae5f4b09fc79d2ebce2
content hash: f713717de7e05fa00fd99206d9badcf1636f89f2458e857132650fd05a281780
signed: 2026-06-02T19:02:27.768Z
sources: 23 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf